Video Insights
Advertisement
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
Dr. Abid describes when he uses bispecifics versus CAR-T in his practice at the University of Texas Health Science Center.
The farnesyltransferase inhibitor tipifarnib achieved an ORR of 40% and a median duration of response of 3.7 months.
The PETAL Consortium at the Jain Lab integrates AI-informed digital interface as a tool to facilitate clinical decisions.
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
The newer agents have distinguished themselves especially by having safety profiles superior to ibrutinib.
Advertisement
Dr. Rogers debated against Inhye Ahn, MD, on whether therapy with Bruton tyrosine kinase inhibitors can be discontinued.
Dr. Coombs discussed time limited therapies and the phase III AMPLIFY trial of acalabrutinib plus venetoclax in CLL.
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
Brentuximab vedotin plus lenalidomide and rituximab combination showed promising efficacy and potential as bridging therapy.
The past year in CLL care has seen promising new study findings on BTK inhibition and regulatory approvals.
In the FELIX trial, obe-cel, a CAR-T therapy, achieved a 78% response rate and a 97% MRD negativity rate.
Of the 127 patients who received obe-cel infusion, 74% achieved CR/CRi and 95% had MRD negativity.
Treatment with the monoclonal antibody 208 alone, and in combination with duvelisib, extended survival.
Dr. Raddi discusses his study on identifying predictors of response to ESA therapy in patients with lower-risk MDS.
Drs. Winer, Daver, and Abaza discuss how the treatment of AML will evolve in the future.
Patients who received at least three IgG tests were less likely to have severe infections compared with those who didn't.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.